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Torino and 10) Istituto di Ematologia ed Oncologia Clinica “Lorenzo e Ariosto Serágnoli,” Ospedale, S. Orsola-Malpighi, Università di Bologna, Bologna, ItalyAbstractA prospective cohort study was conducted in nine hematology wards at tertiary care centres or at university hospitals located throughout
Italy from January 2009 to December 2012. All of the cases of bacterial bloodstream infection (BBSI) occurring in adult patients with
hematologic malignancies were included. A total of 668 bacterial isolates were recovered in 575 BBSI episodes. Overall, the susceptibility
rates of Gram-negative bacteria were 59.1% to ceftazidime, 20.1% to ciproﬂoxacin, 79.1% to meropenem, 85.2% to amikacin, 69.2% to
gentamicin and 69.8% to piperacillin/tazobactam. Resistance to third-generation cephalosporins was found in 98/265 (36.9%) of
Enterobacteriaceae isolates. Among Klebsiella pneumoniae strains, 15/43 (34.9%) were resistant to carbapenems. Of 66 Pseudomonas
aeruginosa isolates, 46 (69.7%) were multidrug resistant. Overall, the susceptibility rates of Gram-positive bacteria were 97.4% to
vancomycin and 94.2% to teicoplanin. Among the monomicrobial cases of BBSI, the 21-day mortality rate was signiﬁcantly higher for
those caused by Gram-negative bacteria compared to those caused by Gram-positive bacteria (47/278, 16.9% vs. 12/212, 5.6%;
p < 0.001). Among Gram-negative bacteria, the mortality rate was signiﬁcantly higher for BBSI caused by K. pneumoniae, P. aeruginosa,
and Acinetobacter baumannii. Our results conﬁrm the recently reported shift of prevalence from Gram-positive to Gram-negative bacteria
as causative agents of BBSIs among patients with hematologic malignancies and highlight a worrisome increasing frequency in antimicrobial
resistance among Gram-negative bacteria.
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of infectious complications, and bacterial bloodstream in-
fections (BBSIs) represent the most severe among these. The
reported prevalence of BBSIs among HM patients ranges from
11% to 38%, and the crude mortality rate reaches up to 40%
[1–5]. In a recent Italian survey, the incidence ofClin Microbiol Infect 2015; 21: 337–343
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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tients with newly diagnosed HMs was 9.4%, and BBSIs repre-
sented 85.1% of these cases [6].
Gram-positive bacteria have been reported as the most
frequent and signiﬁcantly increasing cause of BBSIs in cancer
patients in the last three decades, with frequencies reaching
76% in 2000 [2]. However, in recent years, a trend reversal in
the epidemiology of BBSIs among patients with HMs has been
demonstrated, and Gram-negative bacteria have been reported
as the prevalent cause of BBSIs in some studies [4,7]. In addi-
tion, the extensive emergence of antimicrobial resistance
among bacteria, especially Gram-negative bacteria (e.g. cepha-
losporin- and/or carbapenem-resistant Enterobacteriaceae and
multidrug-resistant (MDR) Pseudomonas aeruginosa), causing
BBSIs in cancer patients has been highlighted [3,7–9].
The aim of this study was to evaluate the clinical and epide-
miologic characteristics andmortality rates of BBSIs that occurred
in a large cohort of patientswithHMs, with particular emphasis on
the antimicrobial resistance proﬁles of bacterial isolates.Materials and methodsThe present prospective study was conducted in nine hema-
tology wards at tertiary care centres or university hospitals
located throughout Italy from January 2009 to December 2012.
Antibacterial prophylaxis was administered to patients
among all participating centres according to Gruppo Italiano
Malattie Ematologiche dell’Adulto (GIMEMA) criteria [10].
All episodes of BBSIs that occurred in hospitalized patients
aged >18 years with hematologic malignancies were included.
Data collected from the hospital charts and the laboratory
database included patient demographics, disease and disease
stage at time of BBSI, the type of hematopoietic stem cell
transplantation (autologous or allogeneic), and the outcome of
infection; for each bacterial isolate, the antimicrobial suscepti-
bility was determined and analysed. All of the information was
entered into the case report forms and then recorded in a
speciﬁc database. Recurrent infections were excluded; only the
ﬁrst episode per patient was included in our registry.
The ethics committee at each participating site approved the
use of the Haematologic Malignancies Associated Bloodstream
Infections Surveillance (HeMABIS) registry, and informed con-
sent was obtained from each patient.
Deﬁnitions
The following terms were deﬁned before data analysis. BBSI
was deﬁned as an infection that was manifested by (a) the
presence in at least one blood culture that sustained bacterial
growth other than skin contaminants (i.e. diphtheroids, BacillusClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectspp., Propionibacterium spp., coagulase-negative staphylococci
(CoNS), and Micrococci) or (b) the presence in at least 2
consecutive blood cultures that sustained growth of skin con-
taminants. BBSI was deﬁned as related to central venous cath-
eters according to the Centers for Disease Control and
Prevention criteria [11]. Neutropenia was deﬁned as an abso-
lute neutrophil count <500 neutrophils/μL at the onset of BBSI;
neutropenia was considered prolonged if the duration was 10
days.
Bacterial isolates were considered hospital-acquired if the
index culture had been collected >48 hours after admission and
the signs and symptoms of infection had been absent at
admission. If the cultures had been collected <48 hours after
the admission date, the isolate was classiﬁed as healthcare
associated or community acquired [12].
If the infecting pathogen demonstrated resistance (as
determined by in vitro susceptibility testing) to the administered
antimicrobial agent or agents, the initial treatment was classiﬁed
as inadequate.
Statistical analysis
Continuous variables were compared by Student’s t test for
normally distributed variables and the Mann-Whitney U test for
nonnormally distributed variables. Categorical variables were
evaluated by the χ2 or two-tailed Fisher’s exact test. The odds
ratios and 95% conﬁdence intervals were calculated to evaluate
the strength of any association that emerged. Values are
expressed as the means ± standard deviation (SD) (continuous
variables) or as percentages of the group from which they were
derived (categorical variables). Two-tailed tests were used to
determine statistical signiﬁcance; a p value of <0.05 was
considered signiﬁcant. All statistical analyses were performed
by the Intercooled Stata program, version 11, for Windows
(StataCorp, College Station, TX, USA).ResultsA total of 575 episodes of bacterial BBSI were included in our
registry during the study period.
Patient characteristics
The majority (529/575, 92%) of patients were neutropenic. The
epidemiologic and clinical characteristics of the patients with
BBSIs, divided according to neutropenic status, are presented in
Table 1.
Etiologic agents of BBSIs
Because 83/575 (14.4%) episodes of BBSI were polymicrobial, a
total of 668 bacteria were isolated. Table 2 shows the results ofious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 337–343
TABLE 1. Clinical and epidemiologic characteristics of cohort
patients according to neutropenic status
Variable
Neutropenic Nonneutropenic
p(n [ 529) (n [ 46)
Demographic information
Male sex 305 (57.7) 32 (69.6) 0.11
Age (years), mean ± SD 52 ± 14.88 51 ± 15.66 0.85
Characteristics of BBSI
Polymicrobial 77 (14.6) 6 (13.1) 0.77
Monomicrobial due to
Gram-negative bacteria
263 (49.7) 15 (32.6) 0.02
Monomicrobial due to
Gram-positive bacteria
187 (35.3) 25 (54.3) 0.01
Hospital acquired 448 (84.7) 29 (63.0) <0.001
Healthcare associated 29 (5.5) 9 (19.6) <0.001
Community acquired 52 (9.8) 8 (17.4) 0.10
Hematologic malignancy
Acute myeloid leukemia 336 (63.5) 16 (34.8) <0.001
Chronic myeloid leukemia 1 (0.2) 0 0.77
Acute lymphatic leukemia 54 (10.2) 9 (19.6) 0.05
Chronic lymphoid leukemia 3 (0.6) 0 0.61
Non-Hodgkin lymphoma 88 (16.6) 10 (21.7) 0.38
Hodgkin lymphoma 11 (2.1) 2 (4.3) 0.32
Multiple myeloma 30 (5.7) 7 (15.2) 0.01
Other 7 (1.3) 2 (4.3) 0.11
Hematopoietic stem cell
transplantation
180 (34.0) 12 (26.1) 0.27
Autologous 83 (15.7) 2 (4.3) 0.04
Allogeneic matched 68 (12.8) 4 (8.7) 0.41
Allogeneic mismatched 33 (6.2) 7 (15.2) 0.02
Antibiotic prophylaxis 439 (83.0) 27 (58.7) <0.001
Co-trimoxazole 78 (14.7) 8 (17.4) 0.63
Fluoroquinolones 408 (77.1) 19 (41.3) <0.001
Antifungal prophylaxis 377 (71.3) 21 (45.6) <0.001
21-day mortality 72 (13.6) 4 (8.7) 0.34
BBSI, bacterial bloodstream infection.
Values are n (%) unless otherwise noted.
CMI Trecarichi et al. Epidemiology and mortality of BBSIs 339causative bacteria according to the neutropenic status of the
patients. Overall, Gram-negative organisms were recovered in
52.8% (353/668) of the BBSI cases, and Gram-positive bacteria
were recovered in 46.6% (311/668) of cases. Among the Gram-
negative bacteria, Escherichia coli represented the most frequent





Gram negative, total 353 (52.8)
Escherichia coli 187 (27.9)
Klebsiella pneumoniae 43 (6.4)
Enterobacter cloacae 26 (3.4)
Pseudomonas aeruginosa 66 (9.9)
Acinetobacter baumannii 3 (0.4)
Stenotrophomonas maltophilia 9 (1.3)
Gram positive, total 311 (46.6)
Coagulase-negative staphylococci 166 (24.8)
Staphylococcus aureus 11 (1.6)
Viridans group streptococci 36 (5.4)
Streptococcus pneumoniae 2 (0.3)
Enterococcus spp. 67 (10.1)
Enterococcus faecalis 27 (4.1)
Enterococcus faecium 37 (5.5)
Anaerobes 4 (0.6)
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology18.7%), Klebsiella pneumoniae (43/353, 12.2%), and Enterobacter
cloacae (26/353, 7.7%). Among the Gram-positive bacteria,
CoNS were the most common species (166/311, 53.4%), fol-
lowed by Enterococcus spp. (67/311, 21.5%), viridans group
streptococci (VGS) (36/311, 11.5%) and Staphylococcus aureus
(18/311, 5.8%). BBSI caused by Gram-negative bacteria was
signiﬁcantly more frequent in patients with neutropenia
compared to nonneutropenic patients (p 0.006); conversely,
the latter patients were more likely to have BBSI caused by
Gram-positive bacteria (p 0.004).
Antimicrobial resistance proﬁles of Gram-negative
organisms
The antimicrobial susceptibility proﬁles of all Gram-negative
bacteria and of the most frequently isolated bacterial species
(i.e. E. coli, K. pneumoniae, P. aeruginosa and E. cloacae) are re-
ported in Table 3. Overall, the susceptibility rates of Gram-
negative bacteria were 59.1% to ceftazidime, 20.1% to cipro-
ﬂoxacin, 79.1% to meropenem, 85.2% to amikacin, 69.2% to
gentamicin and 69.8% to piperacillin/tazobactam. Resistance to
third-generation cephalosporins was found in 98/265 (36.9%) of
Enterobacteriaceae isolates. Among the K. pneumoniae strains,
15/43 (34.9%) were resistant to carbapenems. Of 66
P. aeruginosa isolates, 46 (69.7%) were MDR, as previously
deﬁned [13].
The susceptibility to colistin was tested in 110/353 Gram-
negative isolates, and only two (1.8%; 2 Pseudomonas putida
isolates) of these were resistant. The susceptibility to tige-
cycline was tested in 160/285 Gram-negative isolates other
than Pseudomonas spp., and nine (3.6%; 4 K. pneumoniae, 4
E. cloacae and 1 Acinetobacter baumannii isolates) of these
were resistant.nfections in patients with hematologic malignancies according
Neutropenic Nonneutropenic
p(n [ 616) (n [ 52)
335 (54.4) 18 (34.6) 0.006
181 (29.4) 6 (11.5) 0.006
39 (6.3) 4 (7.7) 0.70
24 (3.9) 2 (3.8) 0.98
63 (10.2) 3 (5.8) 0.30
3 (0.5) 0 0.61
8 (1.3) 1 (1.9) 0.71
277 (44.9) 34 (65.4) 0.004
148 (24.0) 18 (34.6) 0.09
7 (1.1) 4 (7.7) <0.001
35 (5.7) 1 (1.9) 0.25
0 2 (3.8) <0.001
63 (10.2) 4 (7.7) 0.56
24 (3.9) 3 (5.8) 0.51
36 (5.8) 1 (1.9) 0.23
4 (0.6) 0 0.56
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 337–343
TABLE 3. Antimicrobial susceptibility proﬁles of all Gram-negative bacteria and of most frequently isolated bacterial species
Gram negative microorganism Total
Susceptible, n (%)
Ceftazidime Ciproﬂoxacin Meropenem Amikacin Gentamicin Piperacillin/tazobactam
Totala 344 203 (59.1) 69 (20.1) 272 (79.1) 293 (85.2) 238 (69.2) 240 (69.8)
Escherichia coli 187 131 (70.0) 18 (9.6) 184 (98.4) 183 (97.9) 155 (82.9) 156 (83.4)
Klebsiella pneumoniae 43 18 (41.9) 13 (30.2) 28 (65.1) 25 (58.1) 29 (67.4) 19 (44.2)
Enterobacter cloacae 26 12 (46.1) 13 (50.0) 24 (92.3) 23 (88.5) 23 (88.5) 12 (46.1)
Pseudomonas aeruginosa 66 30 (45.4) 13 (19.7) 19 (28.8) 43 (65.1) 15 (22.7) 38 (57.6)
aTotal of Gram-negative bacteria was 344; nine Stenotrophomonas maltophilia isolates were excluded.
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organisms
The antimicrobial susceptibility proﬁles of all Gram-positive
bacteria and of the most frequently isolated bacterial species
(i.e. CoNS, S. aureus, Enterococcus spp., and VGS) are reported
in Table 4. The susceptibility rates to oxacillin were 15.7% and
63.6% for CoNS and S. aureus, respectively. Overall, 40.3% of
the Enterococcus spp. isolates were susceptible to ampicillin; the
susceptibility rates to ampicillin were 88.9% for Enterococcus
faecalis and 5.4% for Enterococcus faecium isolates; 89.2% and
97.3% of E. faecium (and 100% of E. faecalis) isolates were
susceptible to vancomycin and teicoplanin, respectively. Among
the VGS isolates, 63.9% were susceptible to penicillin, whereas
all of these were susceptible to glycopeptides. Overall, the
susceptibility rates of Gram-positive bacteria were 97.4% to
vancomycin and 94.2% to teicoplanin.
Twenty-one-day mortality rates of causative bacterial
isolates from BBSI episodes
Overall, the 21-day mortality rate in patients with BBSIs was
13.2% (76/575); it was higher for patients with polymicrobial
BBSIs (16/83, 19.3%) compared to those with monomicrobial
BBSIs (60/492, 12.2%; p 0.07), those with prolonged neu-
tropenia (56/361, 15.5%) compared to those with neutropenia
with a duration of <10 days (20/214, 9.3%; p 0.03) and those
who had received an inappropriate initial antimicrobial therapyTABLE 4. Antimicrobial susceptibility proﬁles of all Gram-positive
Gram-positive microorganism Total
Susceptible microorganisms, n (%)
Oxacillin Ampicillin Penic
Totala 311 — — —
Coagulase-negative staphylococci 166 26 (15.7) — —
Staphylococcus aureus 11 7 (63.6) — —
Viridans group streptococci a 36 — — 23 (63
Enterococcus spp. 67 — 27 (40.3) —
Enterococcus faecalis 27 — 24 (88.9) —
Enterococcus faecium 37 — 2 (5.4) —
NA, not available.
aSusceptibility rate of viridans group streptococci isolates to ceftriaxone was 94.4% (34/36).
bLinezolid was tested on a total of 156 coagulase-negative staphylococci isolates, and 155 (9
cDaptomycin was tested on a total of 98 coagulase-negative staphylococci isolates, and 97 (9
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect(32/142, 22.5%) versus those who had received an appropriate
empirical antibiotic treatment (44/433, 10.1%; p < 0.001). In
Table 5, the mortality rates for patients with monomicrobial
BBSIs are reported according to the most frequent bacterial
species. Overall, the 21-day mortality rate was signiﬁcantly
higher for patients with BBSI caused by Gram-negative bacteria
compared to those with BBSI caused by Gram-positive bacteria
(47/278, 16.9% vs. 12/212, 5.6%; p < 0.001). Among Gram-
negative bacteria, the mortality rate was signiﬁcantly higher
for BBSI that was caused by K. pneumoniae (p 0.006),
P. aeruginosa (p < 0.001) and A. baumannii (p 0.004). There were
no differences in the mortality rate among BBSIs caused by
Gram-positive bacterial species, except for BBSI that was
caused by VGS and CoNS, which were associated with survival
(p 0.05 and <0.001, respectively). Among the more frequent
antibiotic resistant Gram-negative bacterial species causing
monomicrobial BBSI, the mortality rate was signiﬁcantly higher
for patients with BBSI that was caused by third-generation
cephalosporin-resistant Enterobacteriaceae compared to
third-generation cephalosporin-susceptible Enterobacteriaceae
(22/84, 26.2% vs. 6/124, 4.6%; p < 0.001), for those with BBSI
that was caused by carbapenem-resistant K. pneumoniae
compared to carbapenem-susceptible K. pneumoniae (6/13,
46.1% vs. 3/20, 15%; p 0.04) and for those with BBSI that was
caused by MDR P. aeruginosa compared to non-MDR
P. aeruginosa (14/19, 42.4% vs. 2/16, 12.5%; p 0.03). Thebacteria and of the most frequently isolated bacterial species
illin Vancomycin Teicoplanin Linezolid Daptomycin
303 (97.4) 293 (94.2) — —
164 (98.8) 150 (90.4) 155/156 (99.3)b 97/98 (98.9)c
11 (100) 11 (100) 11 (100) 11 (100)
.9) 36 (100) 36 (100) 36 (100) 36 (100)
62 (92.5) 66 (98.5) 67 (100) NA
27 (100) 27 (100) 27 (100) NA
33 (89.2) 36 (97.3) 37 (100) NA
9.3%) were susceptible.
8.9%) were susceptible.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 337–343
TABLE 5. Stratiﬁcation of 492 patients with monomicrobial bacterial bloodstream infections by most frequent bacterial species
recovered, according to 21-day mortality
Microorganism
Nonsurvivors Survivors
OR (95% CI) p(n [ 60) (n [ 432)
Gram negative, total 47 (78.3) 231 (53.5) 3.14 (1.61–6.51) <0.001
Escherichia coli 16 (26.7) 142 (32.9) 0.74 (0.38–1.40) 0.33
Klebsiella pneumoniae 9 (15.0) 24 (5.6) 3 (1.16–7.12) 0.006
Enterobacter cloacae 3 (5.0) 16 (3.7) 1.37 (0.25–4.99) 0.62
Pseudomonas aeruginosa 16 (26.7) 33 (7.6) 4.40 (2.08–8.97) <0.001
Acinetobacter baumannii 2 (3.3) 1 (0.2) 14.86 (0.75–878.63) 0.004
Stenotrophomonas maltophilia 1 (1.7) 5 (1.2) 1.45 (0.03–13.25) 0.74
Gram positive, total 12 (20.0) 200 (46.3) 0.29 (0.14–0.57) <0.001
Coagulase-negative staphylococci 4 (6.7) 117 (27.1) 0.19 (0.05–0.54) <0.001
Staphylococcus aureus 0 8 (1.8) — 0.29
Viridans group streptococci 0 27 (6.2) — 0.05
Streptococcus pneumoniae 1 (1.7) 1 (0.2) 7.30 (0.09–574.67) 0.10
Enterococcus spp. 4 (6.7) 27 (6.2) 1.07 (0.26–3.24) 0.90
Enterococcus faecalis 0 11 (2.5) — 0.21
Enterococcus faecium 4 (6.7) 15 (3.5) 1.98 (0.46–6.52) 0.23
Anaerobes 1 (1.7) 1 (0.2) 7.30 (0.09–574.67) 0.10
OR, odds ratio; CI, conﬁdence interval.
TABLE 6. Stratiﬁcation of 83 patients with polymicrobial




OR (95% CI) p(n [ 16) (n [ 67)
Only Gram negative 3 (18.7) 13 (19.4) 0.95 (0.15–4.27) 0.95
Only Gram positive 2 (12.5) 23 (34.3) 0.27 (0.02–1.37) 0.08
Both Gram positive
and Gram negative
11 (68.7) 31 (46.3) 2.55 (0.71–10.33) 0.10
OR, odds ratio; CI, conﬁdence interval.
CMI Trecarichi et al. Epidemiology and mortality of BBSIs 341stratiﬁcation of patients with polymicrobial BBSI according to
21-day mortality is reported in Table 6.DiscussionIn this large multicentre Italian cohort study, we examined the
clinical characteristics and the outcome of BBSI episodes in
patients with HMs, as well as the spectrum of susceptibility
patterns of bacterial isolates.
We found that Gram-negative bacteria were the most
frequent microorganisms isolated (52.8%); these data are
consistent with the recently reported shift of prevalence from
Gram-positive toGram-negative bacteria among severe bacterial
infections in patients with cancer [4,7]. In addition, Mikulska et al.,
who recently compared a questionnaire survey conducted in
2011 on the aetiology and resistance in BBSI episodes that
occurred in adult cancer patients in 39 centres (in 18 countries)
to data that was collected from a literature review of BBSI epi-
sodes in adult cancer patients from articles published betweenClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology2005 and 2011, demonstrated that the survey showed a recent
reduction in theGram-positive toGram-negative ratio (55%:45%
vs. 60%:40%) [14]. Notably, the median rate of bacterial species
causing BBSI that was reported in this ECIL-4 questionnaire
survey was similar to the bacterial species distribution in our
cohort, in that E. coliwas the most frequent species (27.9% in our
cohort vs. 30% in the ECIL-4 questionnaire survey), followed by
CoNS (24.8% vs. 24%) and enterococci (10.1% vs. 8%), excepting
the prevalence of P. aeruginosa BBSI, which was twice as high in
our cohort (9.9% vs. 5%) [14].
Regarding antimicrobial susceptibility among Gram-positive
bacteria, we found that the rates were similar or higher
compared to what was reported by Mikulska et al. among adults
in the literature review; in particular, the susceptibility to
methicillin was similar for CoNS (15.7% vs. 20%) but somewhat
higher for S. aureus (63.6% vs. 44%), whereas >92% of staph-
ylococci and enterococci were susceptible to glycopeptides in
our cohort. In addition, we observed a lower prevalence of
vancomycin resistance among E. faecium isolates compared to
previous reports (10.8% vs. 23%) [14]. Similarly, the resistance
to teicoplanin among the CoNS isolates was signiﬁcantly lower
compared to what was previously reported [15].
In contrast, we have found a worrisome trend toward a
decrease in the susceptibility rates to the main antibiotic drugs
among Gram-negative bacteria compared to what has been
reported in more recent epidemiologic studies, which have
been recently reviewed [7]. In particular, only 20.1% of the
Gram-negative bacteria isolates from our patients were sus-
ceptible to ﬂuoroquinolones; the susceptibility rates to ﬂuo-
roquinolones were signiﬁcantly lower compared to those that
were previously reported for E. coli (9.6% vs. 47.2%),
K. pneumoniae (30.2% vs. 61.1%), E. cloacae (50% vs. 95.7%) and
P. aeruginosa (19.7% vs. 51.6%). In addition, we observed ratesand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 337–343
342 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIof susceptibility of 61.5% and 44.2% to meropenem and
piperacillin/tazobactam, respectively, among K. pneumoniae
isolates, which are considerably lower than what was reported
in previous studies (mean of 98.5% and 71.8%, respectively) [7].
We also found a signiﬁcant decrease in the susceptibility rate to
almost all of the most common antibiotics among P. aeruginosa
isolates compared with previous reports: 28.8% vs. 50.1% to
meropenem, 57.6% vs. 78.3% to piperacillin/tazobactam, 45.4%
vs. 62.3% to ceftazidime and 22.7% vs. 78.3% to gentamicin; the
susceptibility of P. aeruginosa isolates in our cohort to amikacin
(65.8%) was similar to what was previously reported (61.8%)
[7]. Approximately 70% of the bloodstream P. aeruginosa iso-
lates were designated MDR in our cohort, and this rate was
similar to what was reported by Cattaneo et al. (71.1%) [16],
though more than twice as high as what was reported in a
preliminary analysis that was conducted by this group on a
smaller population size (33%) [17]. However, it has to be taken
into account that our data are representative of a single
country, and the Italian situation might not be representative
for all of Europe.
Finally, we observed within our cohort a cumulative mor-
tality rate of 13.2%, which is in line with previous reports on
BBSI episodes in adult patients with HMs [8,9,18]. However,
among patients with monomicrobial BBSI, the mortality rate
was signiﬁcantly higher for those with BBSIs that were caused
by Gram-negative bacteria compared to those that were caused
by Gram-positive bacteria. Although this result was expected
and in line with previous large studies [19], some of the more
recent reports evaluating the outcome in bacteremic patients
with HMs according to the Gram stain of causative agents had
not found signiﬁcant differences [8,20–22]. This could be
related to the larger size of our cohort compared to previous
studies, or to the prevalence of Gram-negative bacteria causing
BBSI and the high rate of antimicrobial resistance among these
bacteria, which has been associated with mortality in previous
studies of patients with BBSIs and HMs [20,23]. Conﬁrming this
latter hypothesis, among the Gram-negative bacterial species,
the mortality rates were signiﬁcantly higher for P. aeruginosa, K.
pneumoniae and A. baumannii, which are more frequently
characterized by their patterns of MDR.
In conclusion, our data conﬁrm the recently reported shift in
the prevalence from Gram-positive to Gram-negative bacteria
as causative agents of BBSIs among patients with HMs and
highlight a worrisome increasing frequency in the rate of anti-
microbial resistance among Gram-negative bacteria to all anti-
biotic classes that are recommended for empirical treatments in
this setting. Furthering our understanding of the local distri-
bution of pathogens and their susceptibility patterns and of
patients’ risk factors for resistant bacteria and for a complicated
clinical course, as well as the judicious use of antibiotics andClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectcontrol measures to prevent the development and spread of
antibiotic-resistant Gram-negative bacteria, are necessary steps
that could improve the efﬁcacy of therapeutic treatment pro-
tocols (according to recent recommendations in the European
Conference on Infections in Leukaemia guidelines [24] for
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